Ormat Powers Google’s Data Centers with Clean Geothermal Energy Deal
Ormat Technologies signs a major 150 MW geothermal PPA with NV Energy to supply reliable clean power for Google’s Nevada data centers.
NOTRELOAD AI
Tripadvisor Faces a Major Shake-Up: Activist Investor Starboard Wants Big Changes
Activist investor Starboard Value, holding over 9% of Tripadvisor, is pushing to overhaul the company's board by nominating a majority of new directors. This comes as the stock has dropped sharply amid weak earnings and AI worries.
Cullinan Therapeutics Gets Buy Rating from Citi
Citi gave Cullinan Therapeutics a Buy rating with a $33 target, citing its cancer/autoimmune drug pipeline and key 2026 data readouts as a strong risk/reward opportunity.
Ocular's Axpaxli Beats Eylea in Trial — But Is It Enough to Win Over a Skeptical Market?
Ocular Therapeutix's (OCUL) Axpaxli outperformed a low dose of Regeneron's Eylea in a late-stage wet AMD trial — but narrower-than-expected margins sent shares crashing 27%, raising serious doubts about its commercial future.
Jana Partners Takes Stake in Fiserv: Pushing for a Stock Turnaround
Activist investor Jana Partners has acquired a stake in struggling payments giant Fiserv and is urging changes to boost its lagging share price, while supporting the new CEO's "One Fiserv" plan.
Psilocybin Meets the Bar: Compass Pathways' Dual Phase 3 Wins Signal FDA Filing Ahead
Compass Pathways’ COMP360 psilocybin therapy succeeded in two Phase 3 trials for treatment-resistant depression. Fast relief, lasting effects, and good safety profile – could be the first psilocybin medicine approved by FDA.